Table 3.
Treatment-Related AEs Grade 3 or Higher of Special Interest
| AE | Letrozole + Bevacizumab (%) (n = 173) | Letrozole (%) (n = 170) |
|---|---|---|
| Hypertension | 24 | 2 |
| Proteinuria | 11 | 0 |
| Head or headache pain | 5 | 1 |
| Joint pain | 10 | 0 |
| Left ventricular systolic dysfunction | 2 | 0 |
| Cardiopulmonary arrest | 0 | 1 |
| Cardiac ischemia or infarction | 1 | 0 |
| Thrombosis or embolism | 2 | 1 |
| Wound complications | 1 | 0 |
| CNS hemorrhage | 1 | 1 |
| GI hemorrhage | 1 | 1 |
| CNS cerebrovascular ischemia | 0 | 1 |
NOTE. Reported adverse events (AEs) were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3 with attribution possibly, probably, or definitely related to treatment.